FDA requires expanded labeling about weight loss risk in patients younger than 6 years for extended‐release stimulants
The Food and Drug Administration (FDA) is revising the labeling of all extended‐release stimulants indicated to treat attention‐deficit/hyperactivity disorder (ADHD) — including certain formulations of amphetamine and methylphenidate — to warn about the risk of weight loss and other adverse reactions (side effects) in patients younger than 6 years taking these medications.
Authors
- Alison Knopf
Publication Details
- Journal
- The Brown University Child and Adolescent Behavior Letter
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/cbl.30905
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00